Anti-tumor immune response targets tumor-associated antigens such as cancer testis antigens (e.g., NY-ESO-1 or MAGEs) expressed by several tumors or differentiation antigens (e.g., Melan-A/MART-1, gp100, or tyrosinase) expressed in melanoma cells (Romero et al., 2002; Van Der Bruggen et al., 2002; Boon et al., 2006). Here, MLANA is linked to melanoma.